IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.
Source: medscape.com
Alanj Kivitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Alanj Kivitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Alanj Kivitz Today - Breaking & Trending Today
Alan J. Kivitz, MD: Phase 2b Data on TAK-279 for Psoriatic Arthritis
During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.
Source: hcplive.com
Alan J. Kivitz, MD: Next Steps for Research on TAK-279 for Psoriatic Arthritis
This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.
Source: hcplive.com
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Investegate announcements from Galapagos NV, Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Source: investegate.co.uk